Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer
dc.contributor.author | Kiselev, Yury | |
dc.contributor.author | Andersen, Sigve | |
dc.contributor.author | Johannessen, Charles | |
dc.contributor.author | Fjukstad, Bjørn | |
dc.contributor.author | Olsen, Karina Standahl | |
dc.contributor.author | Stenvold, Helge | |
dc.contributor.author | Al-Saad, Samer | |
dc.contributor.author | Dønnem, Tom | |
dc.contributor.author | Richardsen, Elin | |
dc.contributor.author | Bremnes, Roy M. | |
dc.contributor.author | Busund, Lill-Tove | |
dc.date.accessioned | 2019-01-25T10:21:54Z | |
dc.date.accessioned | 2019-02-26T09:45:23Z | |
dc.date.available | 2019-01-25T10:21:54Z | |
dc.date.available | 2019-02-26T09:45:23Z | |
dc.date.issued | 2018-03-22 | |
dc.identifier.citation | Kiselev Y, Andersen S, Johannessen C, Fjukstad B, Olsen KS, Stenvold S, Al-Saad SAS, Dønnem T, Richardsen ER, Bremnes RM, Busund LTRB. Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer. Scientific Reports. 2018;8 | en |
dc.identifier.issn | 2045-2322 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://hdl.handle.net/10642/6677 | |
dc.description.abstract | Lung cancer is the leading cause of cancer deaths. Novel predictive biomarkers are needed to improve treatment selection and more accurate prognostication. PAX6 is a transcription factor with a proposed tumour suppressor function. Immunohistochemical staining was performed on tissue microarrays from 335 non-small cell lung cancer (NSCLC) patients for PAX6. Multivariate analyses of clinico-pathological variables and disease-specific survival (DSS) was carried out, and phenotypic changes of two NSCLC cell lines with knockdown of PAX6 were characterized. While PAX6 expression was only associated with a trend of better disease-specific survival (DSS) (p = 0.10), the pN+ subgroup (N = 103) showed significant correlation between high PAX6 expression and longer DSS (p = 0.022). Median survival for pN + patients with high PAX6 expression was 127.4 months, versus 22.9 months for patients with low PAX6 expression. In NCI-H661 cells, knockdown of PAX6 strongly activated serum-stimulated migration. In NCI-H460 cells, PAX6 knockdown activated anchorage-independent growth. We did not observe any significant effect of PAX6 on proliferation in either of cell lines. Our findings strongly support the proposition of PAX6 as a valid and positive prognostic marker in NSCLC in node-positive patients. There is a need for further studies, which should provide mechanistical explanation for the role of PAX6 in NSCLC. | en |
dc.description.sponsorship | This study was supported by a grant to Y.K. from Helse Nord (The Northern Norwegian Health Administration). The publication charges for this article have been funded by a grant from the publication fund of UiT The Arctic University of Norway. | en |
dc.language.iso | en | en |
dc.publisher | Nature Research | en |
dc.relation.ispartofseries | Scientific Reports;Volume 8, Article number: 5059 (2018) | |
dc.rights | Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2018 | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Lung cancer | en |
dc.subject | Cancer deaths | en |
dc.subject | Predictive biomarkers | en |
dc.subject | Prognostic markers | en |
dc.subject | Cancer treatment | en |
dc.title | Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2019-01-25T10:21:54Z | |
dc.description.version | publishedVersion | en |
dc.identifier.doi | https://dx.doi.org/10.1038/s41598-018-23417-z | |
dc.identifier.cristin | 1576102 | |
dc.source.journal | Scientific Reports |
Tilhørende fil(er)
Denne innførselen finnes i følgende samling(er)
-
HV - Institutt for naturvitenskapelige helsefag [392]
HV - Department of Life Sciences and Health
Med mindre annet er angitt, så er denne innførselen lisensiert som Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2018